

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

THE GROUP'S "TIROFIBAN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION" WAS GRANTED DRUG REGISTRATION APPROVAL

The board of directors (the “**Board**”) of the CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the “Tirofiban Hydrochloride and Sodium Chloride Injection” (the “**Product**”) developed by the Group has been granted drug registration approval by the National Medical Products Administration of the People’s Republic of China.

Tirofiban is a non-peptide antagonist of the platelet glycoprotein (GP) I**II**b/IIIa receptor which features high selectivity and specificity to platelet I**II**b/IIIa receptors and is able to reversibly inhibit platelet aggregation. It also features a short half-life, no antigenicity and few adverse reactions. Tirofiban is indicated in combination with heparin in patients with unstable angina or non-Q wave myocardial infarction to prevent cardiac ischemia events. It is also indicated in patients with acute coronary syndrome undergoing coronary angioplasty or coronary atherectomy to prevent cardiac ischemic complications associated with sudden occlusion of treated coronary artery.

As compared with tirofiban hydrochloride for injection (lyophilized powder) and tirofiban hydrochloride injection products currently available on the market, the Product eliminates the procedures of dilution and preparation, effectively preventing the risk of contamination and wastage arising from the dilution and preparation procedures during clinical use.

The Product will be able to satisfy the clinical needs of patients and generate good returns to the Group.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 26 November 2018

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Mr. LU Hua, Dr. LI Chunlei, Mr. ZHANG Cuilong, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Professor LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.